Can online consumers contribute to drug knowledge? A mixed-methods comparison of consumer-generated and professionally controlled psychotropic medication information on the internet

Journal of Medical Internet Research

Volumn 13, Issue 3, 2011, Pages

  Hughes, Shannon ^a   Cohen, David ^b  

^a UTAH STATE UNIVERSITY   (United States)

^b FLORIDA INTERNATIONAL UNIVERSITY   (United States)

Author keywords

Consumer health information; Drug monitoring; Internet; Mental health; Pharmacoepidemiology; Postmarketing; Product surveillance; Psychotropic drugs

Indexed keywords

ANTIDEPRESSANT AGENT; CITALOPRAM; DIBENZOTHIAZEPINE DERIVATIVE; QUETIAPINE;

ARTICLE; ATTITUDE TO HEALTH; COMPARATIVE STUDY; CONSUMER; CONSUMER HEALTH INFORMATION; DRUG INFORMATION; HUMAN; INTERNET; METHODOLOGY; PATIENT SATISFACTION; STANDARD; STATISTICS;

ANTIDEPRESSIVE AGENTS; CITALOPRAM; CONSUMER HEALTH INFORMATION; CONSUMER PARTICIPATION; DIBENZOTHIAZEPINES; DRUG INFORMATION SERVICES; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; INTERNET; PATIENT SATISFACTION;

EID: 80053496725     PISSN: None     EISSN: 14388871     Source Type: Journal    
DOI: 10.2196/jmir.1716     Document Type: Article

References (53)

1. Fox S, Jones S. The social life of health information. Washington, DC: Pew Internet & American Life Project; 2009 Jun. URL: http://pewinternet.org/ ~/media//Files/Reports/2009/PIP-Health-2009.pdf [accessed 2010-12-20] [WebCite Cache ID 5v7h0Skmz]
2. Kummervold P, Chronaki C, Lausen B, Prokosch H, Rasmussen J, Santana S, et al. eHealth trends in Europe 2005-2007: a population-based survey. J Med Internet Res 2008;10(4):e42 [FREE Full text] [doi: 10.2196/jmir.1023] [Medline: 19017584]
3. Von Knoop C, Lovich D, Silverstein M, Tutty M. Vital signs: E-health in the United States. Boston, MA: The Boston Consulting Group; 2003. URL: http://www.bcg.com/documents/file14063.pdf [accessed 2010-12-20] [WebCite Cache ID 5v7i9vt4m]
4. Brown P. WHO calls for a health domain name to help consumers. BMJ 2002 Mar 9;324(7337):566 [FREE Full text] [Medline: 11884314]
5. Fox S. Health sites: some are more equal than others.: Pew Internet & American Life Project; 2010 Jan 21. URL: http://www.pewinternet.org/Commentary/ 2010/January/Health-Sites-Some-Are-More-Equal-Than-Others.aspx [accessed 2010-12-20] [WebCite Cache ID 5v7iFMYn4]
6. The Google algorithm.: The New York Times; 2010 Jul 14. URL: http://www.nytimes.com/2010/07/15/opinion/15thu3.html?-r=1 [accessed 2010-12-20] [WebCite Cache ID 5v7iJIBsz]
7. Introna L, Nissenbaum H. Defining the Web: the politics of search engines. Computer 2000;33(1):54-62. (Pubitemid 32212232)
8. Eysenbach G, Powell J, Kuss O, Sa ER. Empirical studies assessing the quality of health information for consumers on the world wide web: a systematic review. JAMA 2002;287(20):2691-2700 [FREE Full text] [Medline: 12020305] (Pubitemid 34533548)
9. Lewis T. Seeking health information on the Internet: lifestyle choice or bad attack of cyberchondria. Media, Culture & Society 2006;28(4):521-539. (Pubitemid 43936794)
10. Speight J, Barendse SM. FDA guidance on patient reported outcomes. BMJ 2010;340:c2921. [Medline: 20566597]
11. Wise J. NHS publishes new data on patient reported health outcomes. BMJ 2010;341:c5143. [doi: 10.1136/bmj.c5143]
12. Bhinder S, Chowdhury N, Granton J, Krahn M, Tullis D, Waddell T, et al. Feasibility of internet-based health-related quality of life data collection in a large patient cohort. J Med Internet Res 2010;12(3):e35 [FREE Full text] [doi: 10.2196/jmir.1214] [Medline: 20719740]
13. Jones JB, Snyder CF, Wu AW. Issues in the design of Internet-based systems for collecting patient-reported outcomes. Qual Life Res 2007 Oct;16(8):1407-1417. [doi: 10.1007/s11136-007-9235-z] [Medline: 17668293] (Pubitemid 47459875)
14. Madan A, Borckardt JJ, Connell A, Book SB, Campbell S, Gwynette MF, et al. Routine assessment of patient-reported outcomes in behavioral health: room for improvement. Qual Manag Health Care 2010;19(1):70-81. [doi: 10.1097/QMH.0b013e3181ccbc53] [Medline: 20042935]
15. Barker KK. Electronic support groups, patient-consumers, and medicalization: the case of contested illness. J Health Soc Behav 2008 Mar;49(1):20-36. [Medline: 18418983]
16. Griffiths KM, Calear AL, Banfield M. Systematic review on Internet Support Groups (ISGs) and depression (1): Do ISGs reduce depressive symptoms? J Med Internet Res 2009;11(3):e40 [FREE Full text] [doi: 10.2196/jmir.1270] [Medline: 19793719]
17. Powell J, McCarthy N, Eysenbach G. Cross-sectional survey of users of Internet depression communities. BMC Psychiatry 2003 Dec 10;3:19 [FREE Full text] [doi: 10.1186/1471-244X-3-19] [Medline: 14664725]
18. Davis JJ, Cross E, Crowley J. Pharmaceutical websites and the communication of risk information. J Health Commun 2007;12(1):29-39. [doi: 10.1080/10810730601091326] [Medline: 17365347]
19. Macias W, Lewis L. A content analysis of direct-to-consumer prescription drug websites. J Advert 2003;32(4):43-56. (Pubitemid 38651616)
20. Waack KE, Ernst ME, Graber MA. Informational content of official pharmaceutical industry web sites about treatments for erectile dysfunction. Ann Pharmacother 2004 Dec;38(12):2029-2034. [doi: 10.1345/aph.1E251] [Medline: 15507499] (Pubitemid 40169370)
21. Schröder S, Zöllner YF, Schaefer M. Drug related problems with Antiparkinsonian agents: consumer Internet reports versus published data. Pharmacoepidemiol Drug Saf 2007 Oct;16(10):1161-1166. [doi: 10.1002/pds.1415] [Medline: 17486665] (Pubitemid 350020071)
22. Moncrieff J, Cohen D, Mason JP. The subjective experience of taking antipsychotic medication: a content analysis of Internet data. Acta Psychiatr Scand 2009 Aug;120(2):102-111. [doi: 10.1111/j.1600-0447.2009.01356.x] [Medline: 19222405]
23. Wicks P, MacPhee GJ. Pathological gambling amongst Parkinson's disease and ALS patients in an online community (PatientsLikeMe.com). Mov Disord 2009 May 15;24(7):1085-1088. [doi: 10.1002/mds.22528] [Medline: 19353722]
24. Wicks P, Massagli M, Frost J, Brownstein C, Okun S, Vaughan T, et al. Sharing health data for better outcomes on PatientsLikeMe. J Med Internet Res 2010;12(2):e19 [FREE Full text] [doi: 10.2196/jmir.1549] [Medline: 20542858]
25. The Association of the British Pharmaceutical Industry. 2007. Facts and statistics from the pharmaceutical industry, top pharmaceutical products in the UK URL: http://www.abpi.org.uk/statistics/section.asp?sect=2 [accessed 2010-12-20] [WebCite Cache ID 5v7lKHP85]
26. IMS Health. 2008. Top 15 global products URL: http://www.imshealth.com/ deployedfiles/imshealth/Global/Content/StaticFile/Top-Line-Data/ Global-Top-15-Products.pdf [accessed 2010-12-20] [WebCite Cache ID 5v7lPD3Qm]
27. IMS Health. 2008. Top 15 products by U.S. sales URL: http://www. imshealth.com/deployedfiles/imshealth/Global/Content/StaticFile/Top-Line-Data/ 2008-Top-15-Products-by-U.S.-Sales.pdf [accessed 2010-12-20] [WebCite Cache ID 5v7lSw8sr]
28. Drugs.com. 2010. Top 200 drugs for 2009 by sales URL: http://www.drugs.com/top200.html [accessed 2011-04-05] [WebCite Cache ID 5xj9CVw2h]
29. Stahl S. Stahl's Essential Psychopharmacology: The Prescriber's Guide. Cambridge, England: Cambridge University Press; 2009.
30. Peladeau, N. QDA Miner Version 3.2 [computer program]. Montreal: Provalis Research; 2009.
31. Eysenbach G, Till JE. Ethical issues in qualitative research on internet communities. BMJ 2001 Nov 10;323(7321):1103-1105 [FREE Full text] [Medline: 11701577] (Pubitemid 33063356)
32. Corbin J, Strauss A. Basics of Qualitative Research: Techniques and Procedures for Developing Grounded Theory. 3rd edition. Thousand Oaks, CA: Sage Publications, Inc; 2008.
33. Krippendorf K. Content Analysis: An Introduction to Its Methodology. 2nd edition. Thousand Oaks, CA: Sage Publications; 2004.
34. O'Neill A. DTC Perspectives. 2007. The patient trust deficit in pharmaceutical marketing URL: http://www.dtcperspectives.com/content/editor/ files/The%20Patient%20Trust%20Deficit%20in%20Pharmaceutical%20Marketing.pdf [accessed 2011-04-05] [WebCite Cache ID 5xj9OXPAz]
35. David S, Pinch TJ. Six degrees of reputation: the use and abuse of online review and recommendation systems.: Social Science Research Network; 2005. URL: http://papers.ssrn.com/sol3/papers.cfm?abstract-id=857505 [accessed 2010-12-20] [WebCite Cache ID 5v7laTWh1]
36. Moncrieff J, Cohen D. How do psychiatric drugs work? BMJ 2009;338:b1963. [Medline: 19482870]
37. Cascade E, Kalali AH, Kennedy SH. Real-World Data on SSRI Antidepressant Side Effects. Psychiatry (Edgmont) 2009 Feb;6(2):16-18. [Medline: 19724743]
38. Landén M, Högberg P, Thase ME. Incidence of sexual side effects in refractory depression during treatment with citalopram or paroxetine. J Clin Psychiatry 2005 Jan;66(1):100-106. [Medline: 15669895]
39. Lee KU, Lee YM, Nam JM, Lee HK, Kweon YS, Lee CT, et al. Antidepressant-Induced Sexual Dysfunction among Newer Antidepressants in a Naturalistic Setting. Psychiatry Investig 2010 Mar;7(1):55-59. [doi: 10.4306/pi.2010.7.1.55] [Medline: 20396434]
40. Serretti A, Chiesa A. Treatment-emergent sexual dysfunction related to antidepressants: a meta-analysis. J Clin Psychopharmacol 2009 Jun;29(3):259-266. [doi: 10.1097/JCP.0b013e3181a5233f] [Medline: 19440080]
41. Uher R, Mors O, Hauser J, Rietschel M, Maier W, Kozel D, et al. Changes in body weight during pharmacological treatment of depression. Int J Neuropsychopharmacol 2011 Apr;14(3):367-375. [doi: 10.1017/S1461145710000933] [Medline: 20716398]
42. Mayers A, Baldwin D. Antidepressants and their effect on sleep. Hum Psychopharmacol 2005 Dec;20(8):533-559. [doi: 10.1002/hup.726] [Medline: 16229049] (Pubitemid 43056116)
43. Wilson S, Argyropoulos S. Antidepressants and sleep: a qualitative review of the literature. Drugs 2005;65(7):927-947. [Medline: 15892588] (Pubitemid 40663621)
44. Komossa K, Rummel-Kluge C, Schmid F, Hunger H, Schwarz S, Srisurapanont M, et al. Quetiapine versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev 2010(1):CD006625. [doi: 10.1002/14651858.CD006625. pub2] [Medline: 20091600]
45. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005 Sep 22;353(12):1209-1223 [FREE Full text] [doi: 10.1056/NEJMoa051688] [Medline: 16172203]
46. Rummel-Kluge C, Komossa K, Schwarz S, Hunger H, Schmid F, Lobos CA, et al. Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis. Schizophr Res 2010 Nov;123(2-3):225-233. [doi: 10.1016/j.schres.2010.07.012] [Medline: 20692814]
47. Leslie DL, Mohamed S, Rosenheck RA. Off-label use of antipsychotic medications in the department of Veterans Affairs health care system. Psychiatr Serv 2009 Sep;60(9):1175-1181 [FREE Full text] [doi: 10.1176/appi.ps.60.9.1175] [Medline: 19723731]
48. Philip NS, Mello K, Carpenter LL, Tyrka AR, Price LH. Patterns of quetiapine use in psychiatric inpatients: an examination of off-label use. Ann Clin Psychiatry 2008;20(1):15-20. [doi: 10.1080/10401230701866870] [Medline: 18297582] (Pubitemid 351302398)
49. Stowell KR, Ghinassi FA, Fabian TJ, Nash KC, Haskett RF. Best practices: an intervention to promote evidence-based prescribing at a large psychiatric hospital. Psychiatr Serv 2009 Mar;60(3):294-296 [FREE Full text] [doi: 10.1176/appi.ps.60.3.294] [Medline: 19252040]
50. Strom BL. How the US drug safety system should be changed. JAMA 2006 May 3;295(17):2072-2075. [doi: 10.1001/jama.295.17.2072] [Medline: 16670415] (Pubitemid 44794008)
51. Davies M. Listening to consumers in a highly regulated environment: How pharmaceutical manufacturers can leverage consumer-generated media.: The Nielsen Company; 2008. URL: http://blog.nielsen.com/nielsenwire/wp-content/uploads/ 2009/11/Nielsen-Online-Healthcare-Practice-Social-Media-Adverse-Event-Reporting- nov09.pdf [accessed 2011-04-05] [WebCite Cache ID 5xj9dEyD3]
52. Hughes S, Cohen D. Understanding the assessment of psychotropic drug harms in clinical trials to improve social workers' role in medication monitoring. Soc Work 2010 Apr;55(2):105-115. [Medline: 20408352]
53. Safer DJ. Design and reporting modifications in industry-sponsored comparative psychopharmacology trials. J Nerv Ment Dis 2002 Sep;190(9):583-592. [doi: 10.1097/01.NMD.0000030522.74800.0D] [Medline: 12357091]